|
Abbreviated name: DLL4
Compound class:
Endogenous peptide in human, mouse or rat
Comment: DLL4 is a 685 amino acid, peptide Notch receptor ligand expressed on the membranes of vascular endothelial cells [4]. DLL4 is a molecular target for the development of anti-cancer therapies [3].
Species: Human
|
| References |
|
1. Gurney A, Axelrod F, Hoey T, Satyal S. (2010)
Anti-human DLL4 antibodies and compositions. Patent number: US7750124 B2. Assignee: Oncomed Pharmaceuticals, Inc.. Priority date: 29/09/2006. Publication date: 06/07/2010. |
|
2. Kopan R, Ilagan MX. (2009)
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell, 137 (2): 216-33. [PMID:19379690] |
|
3. Previs RA, Coleman RL, Harris AL, Sood AK. (2015)
Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res, 21 (5): 955-61. [PMID:25388163] |
|
4. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, Kintner CR, Stark KL. (2000)
Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev, 14 (11): 1313-8. [PMID:10837024] |
|
5. Wilson A, Radtke F. (2006)
Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett, 580 (12): 2860-8. [PMID:16574107] |
